We sought to predict analgesic response to daily oral nonsteroidal anti-inflammatory drugs (NSAIDs) or subcutaneous tanezumab 2.5聽mg (every 8聽weeks) at week聽16 in patients with moderate-to-severe osteoarthritis, based on initial treatment response over 8聽weeks.
Browse by Audience
Skip to content